AI Article Synopsis
- * Leptin production is significantly reduced in individuals with generalized lipodystrophy, where fat is nearly absent, compared to partial forms where some fat is present but can be unevenly distributed.
- * Leptin replacement therapy, specifically with metreleptin, has shown promise in treating metabolic complications linked to lipodystrophy, and newer treatments involving monoclonal antibodies targeting leptin receptors are currently being explored.
Article Abstract
Lipodystrophy syndromes are rare diseases of genetic or acquired origin, characterized by quantitative and qualitative defects in adipose tissue. The metabolic consequences of lipodystrophy syndromes, such as insulin resistant diabetes, hypertriglyceridemia and hepatic steatosis, are frequently very difficult to treat, resulting in significant risks of acute and/or chronic complications and of decreased quality of life. The production of leptin by lipodystrophic adipose tissue is decreased, more severely in generalized forms of lipodystrophy, where adipose tissue is absent from almost all body fat depots, than in partial forms of the disease, where lipoatrophy affects only some parts of the body and can be associated with increased body fat in other anatomical regions. Several lines of evidence in preclinical and clinical models have shown that leptin replacement therapy could improve the metabolic complications of lipodystrophy syndromes. Metreleptin, a recombinant leptin analogue, was approved as an orphan drug to treat the metabolic complications of leptin deficiency in patients with generalized lipodystrophy in the USA or with either generalized or partial lipodystrophy in Japan and Europe. In this brief review, we will discuss the benefits and limitations of this therapy, and the new expectations arising from the recent development of a therapeutic monoclonal antibody able to activate the leptin receptor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ando.2024.05.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health-related quality of life, social and psychological well-being of 109 adult patients with genetic lipodystrophy.
J Clin Endocrinol Metab
December 2024
Université Paris Cité, ECEVE UMR 1123, INSERM, Paris, France.
Introduction: Lipodystrophy syndromes are rare diseases characterized by a generalized or partial lipoatrophic morphotype and metabolic complications. Data on health-related quality of life and impact of genetic lipodystrophy on social or psychological well-being are lacking.
Patients And Methods: Patients with genetic lipodystrophy were recruited throughout the French national reference network for rare diseases of insulin secretion and insulin sensitivity.
Case Report: Concurrent pathogenic variants in the gene as a cause of sporadic partial lipodystrophy.
Front Genet
November 2024
Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Introduction: Inherited lipodystrophies are a group of rare diseases defined by severe reduction in adipose tissue mass and classified as generalized or partial. We report a non-familial (sporadic) case of partial lipodystrophy caused by a novel genetic mechanism involving closely linked pathogenic variants in the gene.
Methods: A female adult with partial lipodystrophy and her parents were evaluated for gene variants across the exome under different mendelian inheritance models (autosomal dominant, recessive, compound heterozygous, and X-linked) to find pathogenic variants.
Autophagy-dependent hepatocyte secretion of DBI/ACBP induced by glucocorticoids determines the pathogenesis of cushing syndrome.
Autophagy
December 2024
Metabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institut, Villejuif, France.
DBI/ACBP is a phylogenetically ancient hormone that stimulates appetite and lipo-anabolism. In response to starvation, DBI/ACBP is secreted through a noncanonical, macroautophagy/autophagy-dependent pathway. The physiological hunger reflex involves starvation-induced secretion of DBI/ACBP from multiple cell types.
View Article and Find Full Text PDFImpact of strength training on reducing risk of fractures in people living with Human Immunodeficiency virus.
J Bodyw Mov Ther
March 2025
School of Nursing of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. Electronic address:
Article Synopsis
- The study examines how strength training affects fracture risk in HIV-positive individuals, highlighting that ART can lead to decreased bone mineral density and higher fracture risk.
- Sixteen inactive HIV-positive men underwent 12 weeks of strength training, with improvements in femoral neck bone density and reduced fracture risk observed after the program.
- Results indicated a significant reduction in fracture risks (24.79% for major fractures, 72.85% for femoral neck fractures) and an increase in bone and muscle mass, suggesting strength training benefits for this population, although more research is needed.*
Gain of function NOTCH3 variants cause familial partial lipodystrophy due to activation of senescence pathways.
Diabetes
December 2024
Departments of Biophysics and Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 7539.
Despite elucidation of the molecular genetic basis of several lipodystrophy syndromes, molecular defects in some ultra-rare subtypes of familial lipodystrophies remain unidentified. We analyzed whole exome sequencing (WES) data of four affected and two unaffected females from an undiagnosed autosomal dominant familial partial lipodystrophy (FPL) pedigree and identified only one novel heterozygous variant, p.Ala1603Tyr in NOTCH3 meeting the filtering criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!